Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
Taufiq SalahuddinVanessa RichardsonDemetria M McNealKamal HendersonPaul L HessSridharan RaghavanDavid R SaxonJavier A ValleStephen W WaldoP Michael HoGregory G SchwartzPublished in: Diabetes, obesity & metabolism (2020)
This analysis indicates unrealized opportunities to reduce mortality in selected veterans with T2D and CAD via increased GLP-1RA and SGLT2i use.